Solascure - up 66%

In brief

  • Began clinical trials in October 2021.
  • Completed Series A raise of £15m, with funding from industry veterans, institutional venture and strategic investors, in August 2021.
  • Selected for URGO Mentorship Program in 2019.

The company

Solascure are working to revolutionise wound care. Its proprietary technology leverages biomimicry and evidence-based medicine to develop treatments for patients with chronic wounds. Its product, Aurase® Wound Gel, is a hydrogel containing an enzyme – isolated and cloned from medical maggots – being developed to find a solution to inadequate debridement procedures.

Solascure

The numbers

Access co-invested in SolasCure alongside a super angel with a weighted IRR of 66%. Their other investments include Geospock, Healx, and Gelmetix.

Find out more about SolasCure on their website.

Find out more about our fund, Access EIS.

See our quarterly highlights

Looking for a fund that does things differently?

Download our quarterly highlights here, with more information on the performance of our portfolio companies.

Register to download the highlights

Register to learn
more about our data,
fund and venture capital

Register now